Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events.

Pratibha SinghIsabel GoncalvesChristoffer TengrydMihaela NitulescuAna F PerssonFong ToEva BengtssonPetr VolkovMarju Orho-MelanderJan NilssonAndreas Edsfeldt

Published in: Cardiovascular diabetology (2020)

This study points out the importance of statin treatment in affecting plaque biology in T2D. It also implies that other biological components, beyond oxLDL, need to be identified and targeted to further reduce the risk of events among T2D patients receiving statin treatment.

Keyphrases

coronary artery disease
cardiovascular events
cardiovascular disease
low density lipoprotein
type diabetes
combination therapy
drug delivery